IBIO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 16:48):

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States...

Stats
Šios dienos apimtis	5 167.00
Vidutinė apimtis	3.96M
Rinkos kapitalizacija	14.47M
EPS	$0 ( 2024-02-13 )
Kita pelno data	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.110
ATR14	$0.0180 (1.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	Duran Felipe	Buy	35 800	Stock Option (right to buy)
2023-11-01	Brenner Martin	Sell	4 881	Common Stock
2023-10-03	Brenner Martin	Sell	5 267	Common Stock
2023-10-02	Brenner Martin	Sell	4 215	Common Stock
2023-08-28	Brenner Martin	Sell	5 011	Common Stock

INSIDER POWER
85.79
Last 90 transactions
Buy: 50 021 245 \| Sell: 29 398 433

Tūris Koreliacija

Ilgas: -0.10 (neutral)

Trumpas: -0.65 (moderate negative)

Signal:(49.801) Neutral

Ibio Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Ibio Inc Koreliacija - Valiuta/Žaliavos

0.37
( neutral )

0.70
( moderate )

0.00
( neutral )

0.16
( neutral )

-0.13
( neutral )

Ibio Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-1.11M (0.00 %)
EPS:	$-47.87

FY	2023
Pajamos:	$0
Bruto pelnas:	$-1.11M (0.00 %)
EPS:	$-47.87

FY	2022
Pajamos:	$2.38M
Bruto pelnas:	$2.17M (90.94 %)
EPS:	$-2 924.26

FY	2021
Pajamos:	$2.37M
Bruto pelnas:	$909 000 (38.34 %)
EPS:	$-2.97

Financial Reports:

No articles found.

Ibio Inc

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.